Drug Profile
Research programme: ZAP signal transduction inhibitor - Takeda
Latest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator ARIAD Pharmaceuticals
- Class Small molecules
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Transplant rejection
Most Recent Events
- 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
- 12 Nov 2003 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 12 Nov 2003 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)